Linagliptin
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Linagliptin and local guidelines before prescribing.
DPP-4 inhibitor
Mechanism
DPP-4 inhibitor raising incretin levels.
Uses
Type 2 diabetes.
Dosing
- Linagliptin 5 mg daily (no renal dose adjustment - useful in CKD).
Endocrinology: Diabetes - Sitagliptin / linagliptin Type 2 | Sitagliptin 100 mg daily (reduce in CKD). Linagliptin 5 mg daily (no renal adjustment). Not with GLP-1 agonists.
Endocrinology: Diabetes
Side effects
Nasopharyngitis, pancreatitis (rare), arthralgia, bullous pemphigoid.
Interactions
Rifampicin reduces effect; sulfonylureas increase hypoglycaemia.
Contraindications and cautions
Pancreatitis history
Monitoring
HbA1c
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
No renal dose adjustment; stop if pancreatitis suspected.
More from the textbook: uses, cautions and other points
- Linagliptin needs no dose change in kidney disease.
Endocrine: Anatomy Physiology and Pharmacology - Sitagliptin / linagliptin | DPP-4; weight neutral, few hypos; pancreatitis, bullous pemphigoid.
Endocrine: Anatomy Physiology and Pharmacology - DPP-4 inhibitors - dose-adjust (linagliptin needs no adjustment).
Renal: Chronic Kidney Disease - DPP-4 inhibitors (gliptins - linagliptin needs no kidney dose change) - safe, well tolerated.
Medicine of the older adult: .Prescribing and deprescribing in older people
Where it is discussed in the book
- Endocrine: Anatomy Physiology and Pharmacology (3 mentions)
- Endocrinology: Diabetes (2 mentions)
- Renal: Chronic Kidney Disease (1 mention)
- Medicine of the older adult: .Prescribing and deprescribing in older people (1 mention)